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Background: RCTs provide the scientific basis upon which treatment decisions are made. To facilitate
critical review, it is important that methods and results are reported transparently. The aim of this study
was to explore transparency in surgical RCTs with respect to trial registration, disclosure of funding
sources, declarations of investigator conflicts and data-sharing.
Methods: This was a cross-sectional review of published surgical RCTs. Ten high-impact journals
were searched systematically for RCTs published in years 2009, 2012, 2015 and 2018. Four domains of
transparency were explored: trial registration, disclosure of funding, disclosure of investigator conflicts,
and a statement relating to data-sharing.
Results: Of 611 RCTs, 475 were eligible for analysis. Some 397 RCTs (83.6 per cent) were registered on
a trial database, of which 190 (47⋅9 per cent) had been registered prospectively. Prospective registration
increased over time (26 per cent in 2009, 33⋅0 per cent in 2012, 54 per cent in 2015, and 72⋅7 per cent in
2018). Funding disclosure was present in 55⋅0, 65⋅0, 69⋅4 and 75⋅4 per cent of manuscripts respectively.
Conflict of interest disclosure was present in 49⋅5, 89⋅1, 94⋅6 and 98⋅3 per cent of manuscripts across the
same time periods. Data-sharing statements were present in only 15 RCTs (3⋅2 per cent), 11 of which
were published in 2018.
Conclusion: Trial registration, disclosure of funding and disclosure of investigator conflicts in surgical
RCTs have improved markedly over the past 10 years. Disclosure of data-sharing plans is exceptionally
low. This may contribute to research waste and represents a target for improvement.
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Introduction
RCTs are widely considered to provide the best evidence
when evaluating the efficacy of surgical interventions. It
is essential that data, and the method by which they are
obtained, are reported transparently to facilitate open crit-
ical review.
The EQUATOR (Enhancing the QUAlity and Trans-
parency Of health Research) network is an international
initiative established to promote transparent and accurate
reporting of research manuscripts. A number of reporting
checklists now exist, including the CONSORT statement
for RCTs and the PRISMA statement for systematic
reviews1,2. Previous studies have examined compliance
with these checklists, and many have identified a need for
improved reporting of key items, such as the method of
randomization and allocation concealment3. The reporting
of other key administrative information is also important
for facilitating open critical review. One such example
is study registration on a publicly available site with
details about how this record can be accessed4,5. Another
includes the disclosure of funding sources and declara-
tion of investigator conflicts, which permit an appraisal
of independence between commercial and academic
partners5. The availability or absence of original data to
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support the study results should also be reported. This
allows investigators to reproduce, examine and compare
data, while reducing research waste through unnecessary
duplication6–8.
The aim of this study was to investigate the transparency
of surgical RCT manuscripts across four domains of aca-
demic publishing. These were: trial registration, disclosure
of funding sources, declaration of investigator conflicts,
and the provision of data-sharing. A longitudinal assess-
ment was planned to explore the trajectory of change and
to identify priorities for improvement.
Methods
As a review of existing literature, approval by a research
ethics committee was not required. This review was not
eligible for registration on the PROSPERO database
of systematic reviews9 as none of the outcomes was of
direct relevance to patients or research participants.
The results are reported according to the STROBE
checklist10.
Definitions
For the purpose of this study, an RCT was defined as
a clinical study involving human participants randomized
to at least two study groups. Surgery was defined as a
procedure involving an external incision with manipula-
tion of underlying tissues. Minimally invasive procedures
were included within this definition, but studies involv-
ing radiologically guided interventions alone were not.
RCTs exploring perioperative interventions (intraopera-
tive or anaesthetic interventions) were included within the
definition of a surgical trial, provided all other study eli-
gibility criteria were satisfied. Trials were considered to
have been registered prospectively if they were registered
during the same month or before the start date of the
study. All others were considered to have been registered
retrospectively.
Data sources
Six high-impact surgical journals were chosen (Annals of
Surgery, British Journal of Surgery, Surgical Endoscopy,World
Journal of Surgery, American Journal of Transplantation and
Journal of the American College of Surgeons). These reflect
widely read and highly cited journals within the field of
surgery (impact factors (2018): range 2⋅768–9⋅476). In
addition, four high-impact general medicine journals that
include surgical research were chosen (NewEngland Journal
of Medicine, The Lancet, Journal of the American Medical
Association and British Medical Journal). The impact factors
(2018) for these ranged from 27⋅604 to 70⋅670.
Eligibility criteria
RCTs involving adult participants were eligible. RCTs
published in 2009, 2012, 2015 and 2018 were included.
Studies involving children, preclinical/animal models
and other non-clinical/non-interventional studies were
excluded. Owing to the prespecified selection of journals,
all manuscripts were published in the English language.
Study outcomes
The study outcomes were: the presence of trial registration
details; the disclosure of study funding (or statement indi-
cating no funding); the declaration of investigator conflicts
(or statement indicating no conflicts); and the presence of
a data-sharing statement. Trial registration was assessed by
examining manuscripts for a unique registry identifier. It
was assumed that the absence of this identifier indicated an
absence of registration. During the course of the study, this
outcome was refined to consider the timing of registration
(prospective versus retrospective). This was determined by
comparing the dates of registration with the study start
date. The presence of funding disclosures, personal con-
flict declarations and data-sharing statements was assessed
through inspection of the manuscript text. If a funding
statement was not disclosed, evidence of the funding source
was sought from the trial registry to maximize the com-
pleteness of data.
Data collection
All assessments were performed by one of three investi-
gators. A 20 per cent sample was selected and validated
by an independent assessor. All investigators discussed
and agreed the assessment protocol before undertak-
ing assessments, and all had a background of formal
research training. Descriptive variables of interest were:
publication year, journal type (surgical, general med-
ical), recruitment (national, international), number of
centres (single-centre, multicentre), blinding (none,
single-investigator, single-participant, double), surgical
specialty and type of intervention.
Statistical analysis
Data are summarized as frequency with percentage
for categorical items, and as median with interquartile
range (i.q.r.) values for continuous items. Where rel-
evant, the χ2 test was used to compare differences in
© 2020 The Authors. www.bjsopen.com BJS Open
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Fig. 1 PRISMA diagram of study inclusion
Trials identified from included journals
n=611
Title and abstract screened
n=611
Id
en
tif
ic
at
io
n
S
cr
ee
ni
ng
In
cl
ud
ed
Detailed screening of full article
n=475
Studies included
n=475
Excluded n=136
 Secondary analysis n=49
 Animal study n=25
 Paediatric study n=14
 Non-clinical study n=45
 Non-randomized study n=3
categorical trial design variables. Subgroup analyses for
each outcome were performed for key study character-
istics, including funding, number of centres, blinding,
study intervention and sample size. Statistical signifi-
cance was set at the level of P< 0⋅050. All analyses were
performed using SPSS® version 21.0 (IBM, Armonk,
New York, USA).
Results
A total of 611 RCTs were considered for inclusion and
475 were determined to be eligible (Fig. 1). Most RCTs
were studies involving gastrointestinal (347, 72⋅6 per
cent), cardiothoracic (27, 5⋅7 per cent) and vascular (21,
4⋅4 per cent) surgery (Table 1). The most common types
of intervention were operative/perioperative (275, 58⋅7
per cent) and drug therapies (146, 29⋅9 per cent). The
median number of participants across all RCTs was 138
(i.q.r. 79–311).
Trial registration
Trial registration on a public database was disclosed in 397
of the 475 RCTs (83⋅6 per cent). The most commonly
used database was ClinicalTrials.gov (276, 69⋅5 per cent),
followed by the ISRCTN registry (38, 9⋅6 per cent) and
UMIN clinical trials registry (18, 4⋅5 per cent). Registra-
tion of RCTs increased chronologically, with 73 of 109
(67⋅0 per cent) registered in 2009, 115 of 137 (83⋅9 per
Table 1 Characteristics of included studies
No. of trials (n = 475)
Year
2009 109 (22⋅9)
2012 137 (28⋅8)
2015 111 (23⋅4)
2018 118 (24⋅8)
Journal type
Surgical 364 (76⋅6)
General medicine 111 (23⋅4)
Recruitment
National 377 (79⋅4)
International 96 (20⋅2)
Unknown 2 (0⋅4)
Centres
Single-centre 264 (55⋅6)
Multicentre 211 (44⋅4)
Blinding
None 175 (36⋅8)
Single, investigator* 70 (14⋅7)
Single, participant 30 (6⋅3)
Double 140 (29⋅5)
Unknown 60 (12⋅6)
Subspecialty
Gastrointestinal 347 (73⋅1)
Cardiothoracic 27 (5⋅7)
Vascular 21 (4⋅4)
Breast 17 (3⋅6)
Urology 11 (2⋅3)
Orthopaedics 13 (2⋅7)
Gynaecology 13 (2⋅7)
ENT 11 (2⋅3)
Miscellaneous 9 (1⋅9)
Neurosurgery 3 (0⋅6)
Plastics 3 (0⋅6)
Intervention
Operative† 275 (57⋅9)
Drug 146 (30⋅7)
Medical device 35 (7⋅4)
Investigation‡ 19 (4⋅0)
Values in parentheses are percentages. *Surgeon or assessor blinding.
†Includes operative and perioperative interventions. ‡Includes diagnostic
tools and imaging interventions.
cent) in 2012, 99 of 111 (89⋅2 per cent) in 2015, and 110
of 118 (93⋅2 per cent) in 2018 (Fig. 2). Of the 397 regis-
tered RCTs, 190 (47⋅9 per cent) were registered prospec-
tively. This also increased chronologically, with 19 (26 per
cent) in 2009, 38 (33⋅0 per cent) in 2012, 53 (54 per cent)
in 2015, and 80 (72⋅7 per cent) in 2018. There were no
statistically significant differences in the presence of regis-
tration between types of funding source, study blinding or
© 2020 The Authors. www.bjsopen.com BJS Open
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Fig. 2 Changes in transparency of reporting between 2009 and 2018
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Table 2 Trial registration
Trial registered
retrospectively (n = 207)
Trial registered
prospectively (n = 190)
Trial not
registered (n = 78)
Total
(n = 475) P¶
Funding* 0⋅217
Non-industry 150 (50⋅3) 122 (40⋅9) 26 (8⋅7) 298
Industry 44 (40⋅7) 54 (50⋅0) 10 (9⋅3) 108
Unknown† 13 (19) 14 (20) 42 (61) 69
Centres <0⋅001
Single-centre 119 (45⋅1) 85 (32⋅2) 60 (22⋅7) 264
Multicentre 88 (41⋅7) 105 (49⋅8) 18 (8⋅5) 211
Blinding 0⋅127
None/open-label 89 (50⋅9) 62 (35⋅4) 24 (13⋅7) 175
Single 46 (46⋅0) 40 (40⋅0) 14 (14⋅0) 100
Double 53 (37⋅9) 70 (50⋅0) 17 (12⋅1) 140
Unknown† 19 (32) 18 (30) 23 (38) 60
Intervention 0⋅392
Operative‡ 130 (47⋅3) 99 (36⋅0) 46 (16⋅7) 275
Drug 54 (37⋅0) 70 (47⋅9) 22 (15⋅1) 146
Device 15 (43) 13 (37) 7 (20) 35
Investigation§ 8 (42) 8 (42) 3 (16) 19
Sample size < 0⋅001
≤100 76 (44⋅2) 46 (26⋅7) 50 (29⋅1) 172
>100 131 (43⋅2) 144 (47⋅5) 28 (9⋅2) 303
Values in parentheses are percentages. *Where funding source was not disclosed, the trial registry was inspected for this information. †Unknown cases
excluded from statistical tests. ‡Includes operative and perioperative interventions. §Includes diagnostic tools and imaging interventions. ¶χ2 test.
the study intervention. Multicentre RCTs were associated
with higher compliance regarding prospective registration
compared with single-centre RCTs (49⋅8 versus 32⋅2 per
cent respectively; P< 0⋅001). Likewise, RCTswith a sample
size greater than 100 were associated with higher compli-
ance than those with smaller sample sizes (47⋅5 versus 26⋅7
per cent respectively; P< 0⋅001) (Table 2).
Disclosure of funding sources
Of 475 RCTs, 315 (66⋅3 per cent) disclosed the presence
or absence of funding sources. Presence of a funding
statement increased over time, with statements disclosed
in 60 RCTs (55⋅0 per cent) in 2009, 89 (65⋅0 per cent) in
2012, 77 (69⋅4 per cent) in 2015, and 89 (75⋅4 per cent)
in 2018. There was no statistically significant difference
© 2020 The Authors. www.bjsopen.com BJS Open
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Table 3 Funding statement
Funding statement
disclosed (n = 315)
Funding statement
not disclosed (n = 160) Total (n = 475) P¶
Funding* <0⋅001
Non-industry 211 (70⋅8) 87 (29⋅2) 298
Industry 104 (96⋅3) 4 (3⋅7) 108
Unknown† 0 (0) 69 (100) 69
Centres <0⋅001
Single-centre 141 (53⋅4) 123 (46⋅6) 264
Multicentre 174 (82⋅5) 37 (17⋅5) 211
Blinding 0⋅984
None/open-label 119 (68⋅0) 56 (32⋅0) 175
Single 69 (69⋅0) 31 (31⋅0) 100
Double 96 (68⋅6) 44 (31⋅4) 140
Unknown† 31 (52) 29 (48) 60
Intervention <0⋅001
Operative‡ 162 (58⋅9) 113 (41⋅1) 275
Drug 119 (81⋅5) 27 (18⋅5) 146
Device 22 (63) 13 (37) 35
Investigation§ 12 (63) 7 (37) 19
Sample size <0⋅001
≤100 82 (47⋅7) 90 (52⋅3) 172
>100 233 (76⋅9) 70 (23⋅1) 303
Values in parentheses are percentages. *Where funding source was not disclosed, the trial registry was inspected for this information. †Unknown cases
excluded from statistical tests. ‡Includes operative and perioperative interventions. §Includes diagnostic tools and imaging interventions. ¶χ2 test.
Table 4 Conflict of interest
Conflict of interest statement
Yes (n = 397) No (n = 78) Total (n = 475) P¶
Funding* 0⋅770
Non-industry 256 (85⋅9) 42 (14⋅1) 298
Industry 94 (87⋅0) 14 (13⋅0) 108
Unknown† 47 (68) 22 (32) 69
Centres 0⋅057
Single-centre 213 (80⋅7) 51 (19⋅3) 264
Multicentre 184 (87⋅2) 27 (12⋅8) 211
Blinding 0⋅320
None/open-label 152 (86⋅9) 23 (13⋅1) 175
Single 80 (80⋅0) 20 (20⋅0) 100
Double 117 (83⋅6) 23 (16⋅4) 140
Unknown† 48 (80) 12 (20) 60
Intervention 0⋅017
Operative‡ 233 (84⋅7) 42 (15⋅3) 275
Drug 123 (84⋅2) 23 (15⋅8) 146
Device 23 (66) 12 (34) 35
Investigation§ 18 (95) 1 (5) 19
Sample size <0⋅001
≤100 125 (72⋅7) 47 (27⋅3) 172
>100 272 (89⋅8) 31 (10⋅2) 303
Values in parentheses are percentages. *Where funding source was not disclosed, the trial registry was inspected for this information. †Unknown cases
excluded from statistical tests. ‡Includes operative and perioperative interventions. §Includes diagnostic tools and imaging interventions. ¶χ2 test.
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in funding disclosure between types of blinding. RCTs
funded by industry had higher compliance with funding
disclosure than those with non-industry funding sources
(96⋅3 versus 70⋅8 per cent respectively; P< 0⋅001) (Table 3).
RCTs recruiting from multiple centres (82⋅5 versus 53⋅4
per cent; P< 0⋅001) and those recruiting more than 100
participants (76⋅9 versus 47⋅7 per cent; P< 0⋅001) were
associated with higher compliance than RCTs recruiting
from single centres and with smaller sample sizes. RCTs
involving an operative/perioperative intervention (58⋅9
per cent) were less likely to provide a funding statement
than those involving devices (62⋅9 per cent), investigations
(63 per cent) or drugs (81⋅5 per cent) (P< 0⋅001) (Table 3).
Declarations of conflicts of interest
Disclosure of conflicts of interest was present in 397 of
the 475 RCTs (83⋅6 per cent). This increased chronolog-
ically, with statements provided in 54 (49⋅5 per cent) of
RCTs in 2009, 122 (89⋅1 per cent) in 2012, 105 (94⋅6 per
cent) in 2015, and 116 (98⋅3 per cent) in 2018. There
were no significant differences in the reporting of conflicts
between funding sources, number of centres, or types of
blinding. RCTs recruiting more than 100 participants were
more likely to report a conflict of interest statement than
those recruiting smaller samples (89⋅8 versus 72⋅7 per cent;
P< 0⋅001). RCTs studying a device (66 per cent) were less
likely to report a statement than those studying a drug (84⋅2
per cent), an operative/perioperative intervention (84⋅7 per
cent) or an investigation (95 per cent) (P = 0⋅017) (Table 4).
Disclosure of data-sharing plans
Data-sharing statements were present in only 15 (3⋅2 per
cent) of 475 RCTs; 11 of these were in studies published
most recently, in 2018. Of these 15 manuscripts, 12 stated
that data sets were available on request, two stated that
no additional data were available, and one study made an
anonymized primary data set available as an appendix.
Discussion
This cross-sectional review explored four key domains
of transparency in surgical RCTs. Compliance with trial
registration, disclosure of funding sources and declara-
tions of personal conflicts were good, with considerable
improvement over the past 10 years. Across most domains,
compliance was better in RCTs recruiting across multiple
centres with larger sample sizes. In contrast, disclosure
of data-sharing plans was exceptionally low, with only 3⋅2
per cent of RCTs stating whether this was possible and
how data were to be made available. Despite efforts to
improve data-sharing, this still seems to be a key challenge
in surgical publishing.
Reporting practices have been explored previously in
a broad range of RCTs. An analysis of RCTs in ten
high-impact surgical journals between 2009 and 2010
showed that 34⋅9 per cent of published RCTs were not reg-
istered on a clinical trials database, and 21 per cent were
registered after the completion of recruitment11. This is
problematic as it may encourage unexplained deviations
from prospectively determined items for analysis and study
design. Elsewhere, less than 15 per cent of trials published
in psychiatry journals between 2009 and 2013 were reg-
istered prospectively, whereas this was considerably better
(77 per cent) for medical specialty trials published between
2010 and 201512,13. The reporting of data-sharing prac-
tices, funding disclosures and conflict of interest declara-
tions have also been explored previously. In a review of
studies published between 2000 and 2014, only one of 441
studies provided information on how to request original
data14. In the same study, a conflict of interest statement
was provided in only 5⋅6 per cent of studies published in
2000, which improved to 65⋅4 per cent for trials published
in 2014. In a review15 of surgical RCTs published between
2005 and 2010, funding disclosures were provided in 47 per
cent and conflict of interest declarations in 25⋅1 per cent.
Although the present study found greater levels of compli-
ance across both of these domains, the difference may be
explained by the later inclusion period (2009–2018) or the
selection of articles from high-impact journals. As shown
previously16, editorial policy for disclosure of statements is
often variable.
The increasing level of transparency in surgical RCTs is
encouraging as it suggests that the conduct of these studies
is improving. Still, in 2018, registration was retrospective
in 27⋅2 per cent of registered trials, and 6⋅8 per cent
were not registered at all. Potential barriers to prospective
trial registration may include: lack of awareness, error of
omission, or the registration process taking longer than
expected17. Improvements in funding and personal conflict
disclosures should also be considered with some caution,
as these are self-declared and difficult to validate. In a
recent study of robotic surgical trials, financial ties with
industry were undeclared in as many as 40 per cent of
industry-supported studies18.
The results indicate the practice of data-sharing as an
area of persisting challenge. Low levels of data-sharing
may contribute to research waste through unnecessary
duplication of results. For policy-makers this increases the
financial burden of research on healthcare systems, and
for surgeons it reduces the financial resources available
© 2020 The Authors. www.bjsopen.com BJS Open
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to answer other research questions. The ethical and legal
positions of sharing patient-level data can be contentious.
Issues of consent, confidentiality and data security must be
considered, and may present a barrier to studies that have
already completed recruitment. For new studies, these
challenges may be addressed through secure data reposito-
ries and early consideration in the design of protocols and
consent materials19,20.
This study has limitations. The generalizability of the
present findings should be interpreted with caution as the
sample of RCTs was from a collection of high-impact sur-
gical and general medical journals. It is possible that these
journals were more likely to endorse transparent report-
ing policies than those with lower impact factors. As the
same journals were considered over a 10-year period, it is
possible that their impact and editorial policies may have
changed. In assessing RCTs, it was assumed that trials were
not registered if a unique identifier was absent from the
report. This is a necessary limitation because the existence
of numerous databases makes it difficult to locate studies
confidently through manual searches. Some registrations
may have been missed, but the absence of such identi-
fiers can itself be considered a barrier to critical appraisal.
Finally, the present study considered only author-reported
statements of data-sharing. It is not possible to evaluate
compliance with this offer or whether requests for data
would be returned in a timely manner21.
This study provides an overall optimistic outlook on
transparent reporting in surgical RCTs, but highlights an
area of need with respect to data-sharing. This might
reflect a lack of awareness around data-sharing and the pos-
sible gains for research efficiency. Logistical and ethical
challenges associated with sharing data, such as lack of time
and resources to prepare data sets and the absence of a uni-
versal open-access data platform, remain barriers. These
issues should be addressed to determine how data-sharing
practices may be improved.
Coded data from this study are available upon reasonable
request from the corresponding author.
Disclosure
The authors declare no conflict of interest.
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